Blue Jet Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.0 pts less than Nifty Smallcap 250 and 9.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Blue Jet Healthcare reported its Q1 FY26 (quarter ended June 30, 2025) unaudited standalone results. Revenue from operations jumped to ₹354.76 crore from ₹162.90 crore in the same quarter last year, more than doubling year-on-year. Total income rose to ₹363.01 crore versus ₹171.61 crore in Q1 FY25. Profit before tax climbed sharply to ₹122.86 crore (from ₹49.47 crore), while net profit surged to ₹91.17 crore (from ₹37.78 crore), translating to an EPS of ₹5.26. The company, which makes artificial sweeteners, contrast media intermediates, and pharma intermediates/APIs, has no subsidiaries, associates, or joint ventures, so only standalone results are reported. The statutory auditor, KKC & Associates LLP, issued an unmodified limited review conclusion with no qualifications.
A standout quarter with revenue and profit more than doubling year-on-year, alongside expanding margins, likely to be viewed positively by investors and may support short-term share price strength. Investors should note the unusually large gap versus Q1 FY25 base and that the Q4 FY25 figures shown are derived balancing figures rather than standalone audited quarter numbers.